Aurora Cannabis Inc (ACB) stock analysis
Close on Nov 11, 2026Market cap $297.69MP/E –Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Weak6 of 30 checks passed
Aurora Cannabis passes 6 of the 30 checks behind our score; 21 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 1/6
- Past performance
- 0/6
- Financial health
- 5/6
- Dividend
- 0/6
What stands out
No debt
Aurora Cannabis has no borrowings on its latest balance sheet.
Interest well covered
No meaningful interest expense to cover.
Debt covered by cash flow
There is no debt to cover.
Growing faster than the industry
Revenue grew 11.0% over the last twelve months; the Drugs median is 8.0%.
What to watch
Revenue growing under 10% a year
Revenue grew 9.3% a year over the last three fiscal years, short of the 10% we look for.
Gross margin slipping
Gross margin was 42.6% over the last twelve months, against 62.6% a year earlier.
No dividend
Aurora Cannabis has not paid a dividend in the last twelve months.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B against the industry
Needs positive book value.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth1/6
Revenue growing under 10% a year
Revenue grew 9.3% a year over the last three fiscal years, short of the 10% we look for.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing faster than the industry
Revenue grew 11.0% over the last twelve months; the Drugs median is 8.0%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin slipping
Gross margin was 42.6% over the last twelve months, against 62.6% a year earlier.
Past performance0/6
Return on equity
Needs positive equity and five years of results.
Return on invested capital
Needs operating income and invested capital.
Return on equity against the industry
Needs positive equity.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin against the industry
Needs revenue and net income.
Financial health5/6
No debt
Aurora Cannabis has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets cover short-term debts
Current assets are 5.94 times current liabilities.
Bankruptcy risk (Altman Z)
Needs market value, working capital and retained earnings.
Dividend0/6
No dividend
Aurora Cannabis has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Aurora Cannabis. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Medium risk
- Average value traded per day
- $7.56M
- Value traded per 1% price move
- $2.27M
Downside
Medium risk
- Typical loss in a bad month
- 22.4%
- Volatility (annualized)
- 60%
- Sharpe ratio, 1 year
- 0.06
- Beta to the S&P 500 (5Y)
- 1.32
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2017 to 2026
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +11.0% | – | +5.5% | – | |
| Gross profit | -24.5% | – | – | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2019 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | – | -9.9% | – | |
| Return on assets | – | -7.9% | – | |
| Current ratio | – | 1.51 | 5.94 | |
| Debt to equity | – | 0.03 | 0.00 | |
| Net debt to EBITDA | – | 0.12× | – | |
| Interest coverage | – | -8.1× | – | |
| Inventory turnover | – | 1.5× | 1.1× | |
| Capex to revenue | – | 168.7% | – | |
| Diluted shares | – | 80M | 57M |
Cash use needs five years of cash flow figures
Aurora Cannabis does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2022 | -776.0% | 0.12× | 1.37× | -127.3% |
| FY2021 | -282.2% | 0.09× | 1.29× | -33.1% |
| FY2020 | -1221.7% | 0.06× | 1.27× | -100.5% |
| FY2019 | -119.5% | 0.07× | 1.25× | -9.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-C$13.51M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-C$13.51M vs –
- Less leverageLong-term debt to assets fell4.7% → 0.0%
- Better liquidityCurrent ratio rose4.31 → 5.94
- No dilutionShare count did not rise56M → 57M
- Gross margin improvedGross margin up on the prior year62.63% → 42.62%
- More efficientAsset turnover rose– → 0.38
See a number that looks wrong?